Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.

TitlePolymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
Publication TypeJournal Article
Year of Publication2013
AuthorsChen C, Wang F, Wang Z, Li C, Luo H, Liang Y, An X, Shao J, Li Y
JournalCancer chemotherapy and pharmacology
Volume72
Issue2
Pagination315-22
Date Published2013 Aug
Abstract

We evaluated whether DNA repair gene polymorphisms had an effect on clinical outcomes in metastatic/recurrent nasopharyngeal carcinoma (NPC) patients treated with cisplatin-based chemotherapy.

DOI10.1039/c3an00948c
Alternate JournalCancer Chemother. Pharmacol.